Denali Therapeutics Inc. — Director's Dealing 2021

Aug 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-08-19

Reporting Person: Watts Ryan J. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-19	Common Stock	S	1626	$49.38	Disposed	2177450	Indirect
2021-08-19	Common Stock	S	750	$49.97	Disposed	2176700	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	151691	Direct

Footnotes

F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.81 to $49.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person.

F4: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.81 to $50.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F6: Includes 151,691 restricted stock units.